-
Product Insights
NewLikelihood of Approval Analysis for Recessive X Chromosome Disorders
Overview How likely is it that the drugs in Recessive X Chromosome Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Recessive X Chromosome Disorders Overview A recessive X chromosome disorder,...
-
Sector Analysis
NewBusiness of the Formula One 2024 – Property Profile, Sponsorship and Media Landscape
Reasons to buy the ‘Business of the Formula One’ report: In-depth analysis of sponsorship and media revenue generated for the 2023-24 season. Detailed team analysis by breaking down the main commercial deals around each of the 30 competing teams from both a sponsorship and media perspective. A comprehensive overview and expert insight of the league that is well regarded as the pinnacle of motor racing anywhere in the world. How is our ‘Business of the Formula One’ report unique from...
-
Product Insights
NewLikelihood of Approval Analysis for Stroke
Overview How likely is it that the drugs in Stroke will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Stroke Overview A stroke, also known as a cerebrovascular accident (CVA), is a...
-
Product Insights
NewLikelihood of Approval Analysis for Age Related Macular Degeneration
Overview How likely is it that the drugs in Age Related Macular Degeneration will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Age Related Macular Degeneration Overview Macular degeneration, also known as...
-
Product Insights
NewLikelihood of Approval Analysis for Beta Thalassaemia
Overview How likely is it that the drugs in Beta Thalassaemia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Beta Thalassaemia Overview Beta-thalassemia is a genetic blood disorder characterized by reduced...
-
Product Insights
NewLikelihood of Approval Analysis for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
Overview How likely is it that the drugs in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Overview Familial hypercholesterolemia (FH)...
-
Product Insights
NewNet Present Value Model: Day One Biopharmaceuticals Inc’s Tovorafenib
Empower your strategies with our Net Present Value Model: Day One Biopharmaceuticals Inc's Tovorafenib report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ibrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibrutinib in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibrutinib in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibrutinib in Transitional Cell Carcinoma (Urothelial Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibrutinib in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibrutinib in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibrutinib in Marginal Zone B-cell Lymphoma Drug Details: Ibrutinib...